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Breast cancer is a hormone-related disease, and there is ample
evidence that ovarian hormones, i.e. oestrogen and progesterone,
are of principal importance in its development, especially in post-
menopausal women (Key and Pike, 1988; Bernstein and Ross,
1993). Well-established risk factors of the disease such as low
parity (Kvåle et al, 1987), high age at first birth (MacMahon et al,
1970), late menopause (Trichopoulos et al, 1972), and early
menarche (Henderson et al, 1988) are believed to be associated
with increase in oestrogen levels. 
In the early 1980s, animal studies indicated that the pineal
hormone melatonin inhibits the growth of melanoma and breast
cancer in vivo and in vitro (Tamarkin et al, 1981; Narito and Kudo,
1985). In 1987, Stevens proposed the ‘melatonin hypothesis’
(Stevens, 1987), suggesting that exposure to electric power,
including visible light, may reduce pineal production of melatonin
and thereby increase breast cancer rates. Specifically, exposure of
the eyes to light during the night can cause a rapid decrease in the
high nocturnal synthesis and secretion of melatonin. Thus,
increased exposure to nocturnal or diurnal visible light may partly
be related with increasing incidence of breast cancer (Stevens and
Davis, 1996). In totally blind people without ocular perception of
light melatonin production is not suppressed by exposure to visible
light, therefore a reduced risk of breast cancer could be antici-
pated. Studies from Sweden and Finland have shown a lower
breast cancer risk in totally blind women compared to that of the
general female population (Feychting et al, 1998; Verkasalo et al,
1999). A US case-control study also indicated that, overall,
women with bilateral blindness had almost half the risk of devel-
oping breast cancer compared to the control group (Hahn, 1991). 
The aim of our study was to investigate the risk of breast cancer
in a Norwegian cohort of blind or milder visually impaired
women. 
MATERIALS AND METHODS 
The present study was based on data from the Norwegian Registry
of Blindness, including 15 736 women (Hansen et al, 1996).
Medical registration of blind or visually impaired people was initi-
ated in Norway in 1946, and in 1968 the registration became
compulsory for all ophthalmologists. Excluded from the study
were women who died or emigrated before 01.01.1961 or had no
date of registration to the registry (324 persons). For each woman,
we had information on date of birth, personal identification
number, category of visual impairment, and date of registration of
the visual impairment. Data on marital status and age at first birth
was obtained from Statistics Norway in 1997. Since age at first
birth was only available for women born 1935 or later, this infor-
mation was of limited value for our study. 
The categories of visual impairment were defined by an
ophthalmologist according to the classification of the World
Health Organisation (WHO 1980): 1 – moderate low vision (visual
acuity less than 0.3); 2 – severe low vision (visual acuity less than
0.12, i.e., able to count fingers at 5 m); 3 – profound low vision or
moderate blindness (visual acuity less than 0.05, i.e., finger
counting at <3 m, or finger counting NOS); 4 – near total blindness
(visual acuity less than 0.02, i.e., finger counting at <1 m, or light
perception); and 5 – total blindness (no light perception). The
latest degree of the impairment with best correction was used in
the analysis. 
Tables 1 and 2 provide the distribution of the material by degree
of visual impairment, by age at onset of total blindness or registra-
tion of latest visual impairment, and by marital status. In the total
cohort, 3% of the subjects were totally blind. Among the totally
blind women, 69% became blind before age of 65, and 47% were
single, while the visual impairment of the majority of women with
milder degree of visual impairment (74%) was registered at age 65
or higher, and only 20% of these women were never married. 
The follow-up period was from January 1, 1961 to the end of
1997. The start of the follow up was the date of blindness, if any,
or the date of registration of the latest visual impairment. January
1, 1961 was defined as the start of follow up for women who
became blind or were registered before the beginning of the
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the year of entering the study to the date of death or emigration, or
to the end of follow up, December 31, 1997, whichever came first
(150 430 person-years). All members of the cohort were linked by
their personal identification number to the national registration of
date of death or emigration and to the Cancer Registry of Norway
where all types of cancer were identified. 
The analysis was based on a computation of observed and
expected cancer cases. The incidence of cancer in the total female
population of Norway served as a reference entity. The expected
numbers of cancer cases were calculated by using the 5-year, age-
specific incidence rates for the reference entity for each year from
1961 to 1997. Standardized incidence ratios (SIRs) were calculated
and 95% confidence intervals (95% CI) were determined by
assuming a Poisson distribution of the observed cases with the use
of a two-sided test of significance. The actual computation was
performed using a standard computer program (Preston et al, 1993). 
RESULTS 
The present study included 308 breast cancer cases and 1347
cancers of other sites. The overall SIR was 1.02 (95% CI =
0.91–1.14) for breast cancer and 1.04 (95% CI = 0.99–1.10) for all
other cancers combined. The SIRs differed by degree of visual
impairment (Table 3). In totally blind women the SIR for breast
cancer was 0.64 (95% CI = 0.21–1.49), while for women with
milder degree of visual impairment the SIRs varied from 0.92 to
1.22. The SIR for breast cancer was 0.51 based on 3 cases (95%
CI = 0.11–1.49) in women who became totally blind before age of
65, while the SIR was 0.02 (2 cases, 95% CI = 0.12–3.69) for
those who first experienced blindness at age 65 or later. The same
pattern was not observed in women with milder degree of visual
impairment (not in table). Among ever married totally blind
women we observed two breast cancer cases (SIR = 0.42,
95% CI = 0.05–1.54) and 3 cases for never married totally blind
women (SIR = 0.97, 95% CI = 0.20–2.85, not in table). 
For other types of cancer combined, the SIRs for all categories
were similar to the general female population, varied from 1.00 to
1.08. 
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Table 1 Number of Norwegian women with visual impairment and person-
years at risk in the period 1961–1997 by degree of visual impairment 
Degree of visual Impairment Number of women Person-years 
n % n % 
Moderate low vision 6104 40 53150 35 
Severe low vision 3153 20 29486 20 
Profound low vision 2987 19 28840 19 
Near-total blindness 2270 15 26247 18 
Total blindness 396 3 6147 4 
Unknown 502 3 6560 4 
Total 15412 100 150430 100 
Table 2 Number of Norwegian women with visual impairment and person-years at risk in the period 1961–1997 by age at onset of blindness or visual
impairment and by marital status 
Totally blind Visually impaired but not blind 
Number of women Person-years Number of women Person-years 
n % n % n % n % 
Age at onset of blindness or milder visual impairment (years) 
<15 126 32 2939.6 48 821 6 18816.9 14 
15–64 148 37 2427.8 39 2861 20 43712.6 32 
65+ 122 31 779.9 13 10832 74 75193.0 54 
Total 396 100 6147.3 100 14514 100 137723.0 100 
Marital status 
Ever married 206 52 2734.1 44 11265 78 101854.0 74 
Never married 186 47 3381.6 55 2986 20 34217.0 25 
Unknown 4 1 31.6 1 263 2 1651.6 1 
Total 396 100 6147.3 100 14514 100 137723.0 100 
Table 3 Standardized incidence ratios (SIRs) of breast cancer and of all other cancers except breast combined by degree of visual
impairment 
Degree of visual impairment Breast cancer Other cancers, except breast 
Obs. SIR 95% CI Obs. SIR 95% CI 
Moderate low vision 104 0.92 0.76–1.11 534 1.08 0.99–1.17 
Severe low vision 77 1.22 0.96–1.52 274 1.00 0.89–1.12 
Profound low vision 63 1.00 0.77–1.29 274 1.01 0.90–1.14 
Near-total blindness 57 1.21 0.92–1.57 197 1.02 0.89–1.17 
Total blindness 5 0.64 0.21–1.49 32 1.07 0.73–1.51 
Unknown 2 0.27 0.03–0.99 36 1.30 0.91–1.79 
Total 308 1.02 0.91–1.14 1347 1.04 0.99–1.10 DISCUSSION 
The present study showed a low risk of breast cancer among
totally blind women, but the finding was based on few cases. Our
results are consistent with findings from Sweden (Feychting et al,
1998) and Finland (Verkasalo et al, 1999). However, we did not
observe any decrease of breast cancer risk in the Norwegian
women with milder degree of visual impairment, and in this
respect our results correspond with the Swedish, but differ from
the Finnish results. The Finnish authors reported a reduced risk in
most of the categories of visual impairment and a decreasing trend
by the categories. Our finding of an association before age of 65 at
onset of blindness also corresponds with the results from the case-
control study in US (Hahn, 1991). In women with milder degree of
visual impairment, we did not observe the same difference in the
risk by age at onset of visual impairment as we did in totally blind
women. 
Marital status was used in our study as an indicator of parity.
Never married totally blind women had twice the risk of breast
cancer compared to ever married blind women. The risk of
breast cancer in never married blind women did not appear to be
higher than in the total general population, while never married
women with a milder degree of visual impairment had a 39% ex-
cess risk, which altogether indicate a protective effect of blindness.
Nulliparity is a well-established risk factor of breast cancer, and a
high proportion of nulliparous women was registered among blind
women. In our study, as much as 89% of totally blind women born
in 1935 or later were nulliparous, while only 39% of all Norwegian
women born in the same period had not given birth. 
The low risk observed in totally blind women without light
perception is in agreement with the ‘melatonin hypothesis’.
Melatonin is a hormone involved in the regulation of the female
menstrual cycle and circadian rhythm by altering the firing rate of
the gonadotropins and prolactin and, indirectly, the secretion of
oestrogen by the gonads (Tamarkin et al, 1985). Current know-
ledge of melatonin receptors provides theories on how the inacti-
vation of these receptors may cause cancer (Baldwin and Barrett,
1998). The presence of melatonin suppresses cancer growth in
experimental animals and in cell cultures (Liburdy et al, 1993;
Mevissen et al, 1996). It is known that light suppresses the
nocturnal peak of melatonin secretion in humans (Lewy et al,
1980). Since most totally blind women are not (ocularly) receptive
to light, they might not have the potential for decreased melatonin
production by light at night and could thus be protected from
breast cancer through this mechanism (Hahn, 1991). In 1992
Coleman and Reiter suggested that a retrospective cohort study of
blind women, carried out by linking a comprehensive registry of
blind persons to a long-standing cancer registry of adequate
quality, would be able to test the hypothesis that long-term blind-
ness protects against breast cancer (Coleman and Reiter, 1992). 
Our study showed a reduced risk of breast cancer among totally
blind women where age at onset of blindness was important and
our findings give support to the ‘melatonin hypothesis’. Therefore
a multicentre study providing a higher number of breast cancer
cases would be of interest. 
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